Comparison of efficacy of apremilast versus methotrexate in patients with moderate to severe chronic plaque psoriasis
DOI:
https://doi.org/10.66344/jpad.v34i1.2749Keywords:
Efficacy, Apremilast, Methotrexate, Chronic plaque psoriasisAbstract
Background Numerous health-related conditions arise with advancing age. Skin diseases highlight essential global public health priorities. So, this research examines whether or not socio-demographic and clinical factors predict quality of life among older patients with skin diseases.
Methods This cross-sectional and descriptive study was undertaken on 310 older patients with skin diseases referred to Razi Clinic in Rasht, Iran. The convenience sampling method was used to select older patients. A demographic characteristic checklist and Dermatology Life Quality Index (DLQI) were used to collect data. The predicted factors were detected by the multivariate regression model.
Results The mean age of the older patients was 64.51±5.04 years old. Most participants were female (56.9%, n=148), married (83.5%, n=217), and lived with their spouse or spouse and children (82.3%, n=214). Results showed that quality of life was significantly associated with economic situation (β=0.22, p<0.001), type of skin disease (β=-0.33, p<0.001), history of psychological (β=0.20, p =0.009) or physical problems (β=0.12, p =0.042), and duration of skin disease (β=0.24, p=<0.001).
Conclusion The majority of older patients experienced moderate to large impacts of skin diseases on their quality of life. The results of the current study emphasized the impacts of the economic situation and clinical characteristics of older patients on their quality of life.
References
1. Parisi R, Symmons DP, Griffiths CE. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.
2. Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22:663-7.
3. Tribo MJ, Turroja M, Castano-Vinyals G, Bulbena A, Ros E, Gracia-Martinez P, et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Derm Venereol. 2019;99:1-5.
4. Evers AW, Verhoeven EW, Kraaimaat, FW. How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol. 2018;163:986–91.
5. Griffiths C, Barker J, Bleaker T, Chalmers R, Ceamer D. Management of psoriasis and related disorders. Rooks textbook of Dermatology 9th edition. 2016; 35:22-29.
6. Gao JC, Wu AG, Contento MN, Maher JM, Cline A. Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis. Clin Cosmetic Invest Dermatol. 2022;15:395-402.
7. Haider S, Wahid Z, Najam-us-Saher, Riaz F. Efficacy of Methotrexate in patients with plaque type psoriasis. Pak J Med Sci. 2014; 30(5):1050-3.
8. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. The Lancet. 2018; 391(10136):2273-84.
9. Ohtsuki M, Okubo Y, and Komine M. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017; 44(8):873–84.
10. Van Voorhees AS, Gold LS, Lebwohl M, Strober B, Lynde C, Tyring S, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Academy Dermatol. 2020; 83(1):96-103.
11. AbuHilal MD, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutaneous Med Surg. 2016;20(4):313-6.
12. Rosie TN, Khan AL, Khan MS, Yazdi QS, Karim AR. Efficacy and safety of apremilast versus methotrexate in the treatment of chronic plaque psoriasis. J Armed Forces Med Coll, Bangladesh. 2020;16(1):39-41.
13. Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. J Am Academy Dermatol. 2016;75(4):740-6.
14. Thai S, Zhuo J, Zhong Y, Xia Q, Chen X, et al. ,Real- world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. J of Dermatol Treat. 2023 (Accepted author version posted online: 16 Feb 2023) DOI: 10.1080/ 09546634.2023.2176708
15. Lomholt G. Psoriasis: Prevalence, Spontaneous Course and Genetics. A Census Study on the Prevalence of Skin Diseases on the Faroe Islands. Copenhagen: GEC Gad. 2013:31–3.
16. Farber EM, Nall ML. The natural history of psoriasis in 5600 patients. Dermatologica. 2014;148:1–18.
17. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol. 2016;135:533–7.
18. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 2015;13:450-6.
19. Gottlieb, AB., Ryan, C., Murase, JE. Clinical considerations for the management of psoriasis in women. Int J Women Dermatol. 2019;5(3):141-50.
20. M.M. Gawlik, B. Topczewska, D. Kurpas . Quality of life of psoriatic patients – modulatory variables. Fam Med Prim Care Rev. 2016;18(3):235–40.
21. M. Augustin, G. Glaeske, M.A.Radtke, Reich K., Christophers E., Schaefer I., et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633-6.
22. R.S. Stern, T. Nijsten, S.R. Feldman, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-9.
23. Colombo G., Altomare G., Peris K,, Martini P., Quarta G., Congedo M., et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008; 4(2):559-68.
24. Fry L. Psoriasis. Br J Dermatol. 2008; 119(4):445-61.
25. Roenigk HH Jr, Auerbach R, Maibach HI, and Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 2018;19:145-56.
26. Nickoloff BJ, Mitra RS, Green J, Zheng XG, Shimizu Y, Thompson C, et al. Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/ intercellular adhesion molecule-1 interaction. J Immunol. 2013;150(6):2148-59.
27. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382–8.
28. Gottlieb AB, Strober B, Krueger JG. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008; 24:1529-38.
29. Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination surveys. Am J Prev Med. 2014; 47(1):37-45.
30. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-99.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Amna Khalid, Aisha Ghias; Usama Shahbaz, Rutaba Kiran, Abid Hussain, Shahbaz Aman
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
